Reports Q4 revenue $1.51B, consensus $1.51B. “In 2025 we took action that demonstrated our commitment to improving the balance sheet and to building more financial flexibility,” said Joe Morrissey, Organon’s (OGN) interim Chief Executive Officer. “In 2026 our primary objective is to maintain operational performance that aligns with last year. At the same time, we remain committed to disciplined expense management and capital deployment to achieve progress on our deleveraging efforts.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon completes divestiture of JADA System to Laborie
- Organon announces U.S. FDA approved sNDA for Nexplanon
- M&A News: India’s Sun Pharma Eyes $10B Bid for U.S.’ Organon
- Organon and Co put volume heavy and directionally bearish
- Organon, Daiichi Sankyo Europe enter commercialization pact for Nilemdo